Wide Ranks

MGX

Metagenomi, Inc.

2.02

Top Statistics
Market Cap 75 M Forward PE -0.7014 Revenue Growth -6.90 %
Current Ratio 6.18 Trailing PE 0.0000 Earnings Growth 0.00 %
Profit Margins -134.27 % Peg Ratio Dividend Yield 0.00 %
Enterprice / EBITA 1.83 Enterprise / Revenue -2.78 Price To Sales Trailing12 Months 1.37
Profitability
Profit Margins -134.27 % Operating Margins -194.40 %
Balance Sheet
Total Cash 274 M Total Cash Per Share 7.34 Total Debt 46 M
Total Debt To Equity 18.01 Current Ratio 6.18 Book Value Per Share 6.83
All Measures
Short Ratio 123.00 % Message Board Id finmb_633445224 Shares Short Prior Month 369490
Return On Equity -0.3034 City EmeryVille Uuid b9b86ae0-a307-38b5-a501-e7048f92be48
Previous Close 2.01 First Trade Date Epoch Utc 1 B Book Value 6.83
Total Debt 46 M Volume 254495 Price To Book 0.2956
Fifty Two Week Low 1.61 Total Cash Per Share 7.34 Total Revenue 55 M
Shares Short Previous Month Date 1 B Target Median Price 17.00 Max Age 86400
Recommendation Mean 1.57 Sand P52 Week Change 0.3133 Operating Margins -194.40 %
Target Mean Price 17.00 Net Income To Common -73954000 Short Percent Of Float 0.0164
Implied Shares Outstanding 37 M Trailing Peg Ratio None Last Fiscal Year End 1 B
Average Daily Volume10 Day 601550 Average Volume10days 601550 Total Cash 274 M
Next Fiscal Year End 1 B Revenue Per Share 2.24 Held Percent Insiders 0.2881
Ebitda Margins -151.28 % Trailing PE 0.0000 Date Short Interest 1 B
Most Recent Quarter 1 B Regular Market Previous Close 2.01 Target Low Price 7.00
Gmt Off Set Milliseconds -18000000 Fifty Day Average 2.02 Open 1.99
Free Cashflow -73891248 State CA Dividend Yield 0.00 %
Return On Assets -0.1485 Time Zone Short Name EST Trailing Eps -2.24
Day Low 1.96 Address1 5959 Horton Street Shares Outstanding 37 M
Price Hint 4 Target High Price 25.00 Website https://www.metagenomi.co
52 Week Change -0.8041 Average Volume 341201 Forward Eps -2.90
Recommendation Key buy Compensation As Of Epoch Date 1 B Quick Ratio 602.20 %
Is_sp_500 False Regular Market Day High 2.06 Profit Margins -134.27 %
Debt To Equity 18.01 Fifty Two Week High 12.74 Day High 2.06
Shares Short 443564 Regular Market Open 1.99 Industry Key biotechnology
Earnings Growth 0.00 % Enterprise To Revenue -2.78 Revenue Growth -6.90 %
Shares Percent Shares Out 0.0119 Operating Cashflow -103389000 Currency USD
Time Zone Full Name America/New_York Market Cap 75 M Is_nasdaq_100 False
Zip 94608 Quote Type EQUITY Industry Biotechnology
Long Name Metagenomi, Inc. Regular Market Day Low 1.96 Held Percent Institutions 0.3469
Current Price 2.02 Address2 7th Floor Enterprise To Ebitda 1.83
Financial Currency USD Current Ratio 6.18 Gross Margins -71.39 %
Industry Disp Biotechnology Number Of Analyst Opinions 5 Country United States
Float Shares 23 M Two Hundred Day Average 5.48 Enterprise Value -152917680
Price To Sales Trailing12 Months 1.37 Forward PE -0.7014 Regular Market Volume 254495
Ebitda -83327000 Exchange NMS
Go to Yahoo Finance Go to Seeking Alpha 
Metagenomi, Inc., a genetic medicines company, develops therapeutics for patients using metagenomics-derived genome editing toolbox in the United States.

The company's genome editing toolbox includes programmable nucleases, base editors, and RNA and DNA-mediated integration systems, such as prime editing systems and clustered regularly interspaced short palindromic repeat-associated transposases.

It has a development, option, and license agreement with Affini-T Therapeutics, Inc. to develop and commercialize gene edited T-cell receptor-based therapeutic products in the field of treatment, prevention, or diagnosis of human cancer; and a collaboration and license agreement with Ionis Pharmaceuticals, Inc. to research, develop, and commercialize investigational medicines using genome editing technologies.

The company was incorporated in 2016 and is based in Emeryville, California.